Dishman Carbogen Amcis Limited

DCAL

INE385W01011

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 10:52:11 21/05/2026 am IST			5-day change	1st Jan Change
220.98 ^INR	+4.63%		+24.47%	-10.70%

19/05	Dishman Carbogen Amcis Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05/05	Dishman Carbogen Amcis says unit successfully completed GMP inspection by China's NMPA for Shanghai site	RE

Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million

Published on 12/27/2025 at 12:56 pm IST

S&P Capital IQ

DISHMAN CARBOGEN AMCIS LIMITED

+4.63%

Dishman Carbogen Amcis Limited approved issuance of upto 5,000 (Five thousand) Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures of face value of INR 1,00,000 (Rupees One Lac only) each, aggregating up to INR 50,00,00,000 (Rupees Fifty Crores), on a private placement basis (the "Issue" or "Debentures" or "NCDs").

Latest news about Dishman Carbogen Amcis Limited

19/05	Dishman Carbogen Amcis Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05/05	Dishman Carbogen Amcis says unit successfully completed GMP inspection by China's NMPA for Shanghai site	RE
18/03	Dishman Carbogen Amcis Ltd approves issue of up to 1 billion rupees NCDs on Private Placement basis	RE
18/03	Dishman Carbogen Amcis Limited Approves Issue of Senior Secured Rated Listed Redeemable Transferable Taxable Non-Convertible Debentures on Private Placement Basis	CI
05/02	Dishman Carbogen Amcis Limited, Q3 2026 Earnings Call, Feb 04, 2026
03/02	Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
03/02	Dishman Carbogen Amcis Dec-quarter Consol Net Loss After Tax 129.7 Million Rupees	RE
27/12	Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million	CI
23/12	Dishman Carbogen Amcis to consider fund raising via NCDs	RE
05/11	Dishman Carbogen Amcis Limited, Q2 2026 Earnings Call, Nov 05, 2025
04/11	Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
26/25/26	Dishman Carbogen Amcis receives EIR from US FDA indicating inspection closure	RE
13/25/13	Dishman Carbogen Amcis Limited, Q1 2026 Earnings Call, Aug 13, 2025
13/25/13	Dishman Carbogen Amcis Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
27/25/27	Dishman Carbogen Amcis Limited Announces the Demise of Shri Janmejay R. Vyas, Chairman & Non-Executive Director on May 27, 2025	CI

Chart Dishman Carbogen Amcis Limited

Duration

Period

DCAL: Dynamic Chart

Company Profile

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.

Employees

1,106

Sector

Pharmaceuticals

More about the company